about
Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.Altered peroxisome-proliferator activated receptors expression in human endometrial cancer.Hedgehog-mediated regulation of PPARγ controls metabolic patterns in neural precursors and shh-driven medulloblastomaThe role of peroxisome proliferator-activated receptors in the esophageal, gastric, and colorectal cancerAn immunohistochemical perspective of PPAR beta and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours.CD36-dependent regulation of muscle FoxO1 and PDK4 in the PPAR delta/beta-mediated adaptation to metabolic stress.Cancer cell signaling pathways targeted by spice-derived nutraceuticals.Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma AgonistsNO-Donating NSAIDs, PPARdelta, and Cancer: Does PPARdelta Contribute to Colon Carcinogenesis?Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies.Peroxisome proliferator-activated receptors in cardiac energy metabolism and cardiovascular disease.Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?Attenuation of peroxisome proliferator-activated receptor gamma (PPARgamma) mediates gastrin-stimulated colorectal cancer cell proliferation.PPARG Epigenetic Deregulation and Its Role in Colorectal Tumorigenesis.Role of peroxisome proliferator-activated receptors alpha and gamma in gastric ulcer: An overview of experimental evidences.Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo.Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo.Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action.
P2860
Q34659408-027C27EF-9DAC-4B35-A0C8-06201EAA181AQ35789097-B1595543-E3A1-49B7-99E4-A0E420B35B06Q35837389-7C5D98D7-16A0-4EA0-AF00-5484C50FA74CQ36238973-DB206CB3-5F0B-43EF-BCFE-78C761B5E413Q36615627-90671476-8255-44DC-B138-0BB336DC62F6Q36662756-C89BB44B-2CB4-49BF-9317-08B1F6113840Q36819371-237505BE-FD7C-4A06-9C06-39D871D87AE4Q37077098-8CD04F55-D86B-4972-9458-DCC5EB54EF27Q37182798-C4AD45DE-B720-4E07-94DC-AB015C1CEA3CQ38061184-3D5363EE-D7B5-419A-99F7-C3E3927C3698Q38817895-5A5D2896-BBF4-4048-B351-DB633EBD9E50Q40281693-7043388D-8880-468E-87FC-E7C4495BF285Q40297887-DED991B7-0BF4-4303-B6FD-145E393E430CQ42250957-91EBC353-BEAB-4E91-9A4A-96ECF48A2657Q43185880-EF3831B6-3F3D-4D67-A455-A5B6BCFEA1E0Q43461615-F9DAE164-1368-4BE3-90BF-2D2CFB440464Q46766813-349D7FF7-9B0C-49B9-A866-28BF714A5954Q53338744-6FE05991-24FB-4F60-9672-7CF5522E3FED
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
PPAR trilogy from metabolism to cancer.
@ast
PPAR trilogy from metabolism to cancer.
@en
type
label
PPAR trilogy from metabolism to cancer.
@ast
PPAR trilogy from metabolism to cancer.
@en
prefLabel
PPAR trilogy from metabolism to cancer.
@ast
PPAR trilogy from metabolism to cancer.
@en
P1476
PPAR trilogy from metabolism to cancer.
@en
P2093
Zaher Nahlé
P304
P356
10.1097/01.MCO.0000134360.30911.BB
P577
2004-07-01T00:00:00Z